文献速递甲状腺疾病

Graves病:病理生理引导治疗的新时代

Graves' disease: a new era of pathophysiology-guided therapeutics.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

Graves病(GD)的传统治疗(放射性碘、抗甲状腺药物ATD、手术)半个多世纪未变,甲减常被视为可接受的代价,但患者生活质量问题日益受关注。近十年对GD免疫机制的深入探索及经典治疗模式的重校准,推动了以甲状腺保留为目标的ATD长期方案,并涌现出针对TRAb生命周期的免疫靶向干预(减少生成、增强清除、中和受体)。这些方法正在临床试验评估中,结合技术与人工智能,有望实现GD管理的个体化,从甲状腺功能正常化迈向诱导长期缓解和预防相关自身免疫现象。

要点

  • ATD作为首选治疗及长期方案的趋势反映了对甲状腺保留的重视。
  • 免疫靶向干预聚焦TRAb生命周期:B细胞靶向、FcRn抑制剂、TSH受体阻断。
  • 技术与人工智能可能影响GD的识别、治疗和监测。

核心结论

  • GD治疗正从功能正常化转向诱导长期缓解和预防相关自身免疫现象。
  • 免疫靶向干预与经典治疗重校准将推动GD管理的显著个体化。

研究设计与样本

  • 综述类文章,检索范围未明确报告。

主要发现

  • 传统治疗包括放射性碘、ATD和手术,甲减常被视为可接受代价。
  • 对GD免疫机制的探索聚焦于干预TRAb生命周期。
  • ATD作为首选治疗及长期方案的使用增加,反映甲状腺保留的偏好。

临床怎么用

  • 临床可考虑将ATD作为主要治疗并探索长期方案以保留甲状腺。
  • 关注针对TRAb生命周期的免疫靶向干预的临床试验进展。
  • 重视GD患者生活质量和长期缓解的评估。

局限性

  • 免疫靶向方法仍需临床试验评估。
  • 技术与人工智能在GD管理中的应用潜力尚待成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graves' disease (GD) is an autoimmune entity that had an unchanged treatment paradigm for more than half a century with radioactive iodine, antithyroid drugs (ATDs), and surgery representing the mainstay of therapy, with variation in their use over time and geographic location. Hypothyroidism has been an accepted tradeoff in many cases, though recently there are increased concerns about altered quality of life in these patients. Fortunately, the last decade has seen an intense pursuit of GD's immunological mechanisms and a recalibration of classic treatment modalities focusing on thyroid preservation, as reflected in the preference for ATD as primary therapy, including its use in long-term protocols. The immune targets currently explored aim to address this gap by intervening in the TRAb lifecycle: minimizing production (eg, B-cell targeting), enhancing clearance (eg, neonatal Fc receptor inhibitors), or neutralizing its target-the TSH receptor (eg, receptor blockade). While these approaches are going through the necessary clinical trials evaluation, we are starting to see the potential for technology and artificial intelligence to make an impact on how we identify, treat, and monitor patients with GD. The combination of these approaches will likely lead to a significant individualization of GD management that will take us from the goal of normalization of thyroid levels to that of inducing long-term remission and prevention of the associated autoimmune phenomena that GD is associated with. While time is needed for these aspects to mature, the future looks bright for our GD patients and maybe soon these lessons will open new doors for our patients with Hashimoto's thyroiditis as well.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Stan MN, Toro-Tobon D. Graves' disease: a new era of pathophysiology-guided therapeutics. J Clin Endocrinol Metab. 2026. PMID: 41530911. doi:10.1210/clinem/dgag010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。